Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Case Report

Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?

Authors: Rodolfo Montironi, Marina Scarpelli, Roberta Mazzucchelli, Antonio Lopez-Beltran, Matteo Santoni, Alberto Briganti, Francesco Montorsi, Liang Cheng

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Background

There is a worldwide debate involving clinicians, uropathologists as well as patients and their families on whether Gleason score 6 adenocarcinoma should be labelled as cancer.

Case description

We report a case of man diagnosed with biopsy Gleason score 6 acinar adenocarcinoma and classified as low risk (based on a PSA of 5 ng/mL and stage cT2a) whose radical prostatectomy specimen initially showed organ confined Gleason score 3 + 3 = 6, WHO nuclear grade 3, acinar adenocarcinoma with lymphovascular invasion and secondary deposit in a periprostatic lymph node. When deeper sections were cut to the point that almost all the slice present in the paraffin block was sectioned, a small tumor area (<5% of the whole tumor) of Gleason pattern 4 (poorly formed glands) was found in an extraprostatic position.

Conclusion

The epilogue was that the additional finding changed the final Gleason score to 3 + 3 = 6 with tertiary pattern 4 and the stage to pT3a.

Virtual Slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​13000_​2014_​190
Appendix
Available only for authorised users
Literature
1.
Berman DM, Epstein JI: When is prostate cancer really cancer?. Urol Clin North Am. 2014, 41: 339-346. 10.1016/j.ucl.2014.01.006.PubMedCrossRef
2.
Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI: Gleason score 6 adenocarcinoma: should it be labeled as cancer?. J Clin Oncol. 2012, 30: 4294-4296. 10.1200/JCO.2012.44.0586.PubMedPubMedCentralCrossRef
3.
Esserman LJ, Thompson IM, Reid B: Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013, 310: 797-798. 10.1001/jama.2013.108415.PubMedCrossRef
4.
Nickel JC, Speakman M: Should we really consider Gleason 6 prostate cancer?. BJU Int. 2012, 109: 645-646. 10.1111/j.1464-410X.2011.10854.x.PubMedCrossRef
5.
Soloway MSR: Overdiagnosis and overtreatment in cancer: an opportunity for improvement. Eur Urol. 2014, 65: 249-250. 10.1016/j.eururo.2013.10.023.PubMedCrossRef
6.
Mohler JL: The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010, 8: 145-PubMed
7.
Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI: Do adenocarcinomas of the prostate with Gleason score (GS)? 6 have the potential to metastasize to lymph nodes?. Am J Surg Pathol. 2012, 36: 1346-1352. 10.1097/PAS.0b013e3182556dcd.PubMedPubMedCentralCrossRef
8.
Finley DS, Deane L, Rodriguez E, Vallone J, Deshmukh S, Skarecky D, Carpenter P, Narula N, Ornstein DK, Ahlering TE: Anatomic excision of anterior prostatic fat at radical prostatectomy: implications for pathologic upstaging. Urology. 2007, 70: 1000-1003. 10.1016/j.urology.2007.09.028.PubMedCrossRef
9.
Epstein JI: An update of the Gleason grading system. J Urol. 2010, 183: 433-440. 10.1016/j.juro.2009.10.046.PubMedCrossRef
10.
Sobin LH, Gospodarowicz MK, Wittekind C: Urological tumour, prostate. UICC TNM Classification of Malignant Tumours. Edited by: Sobin LH, Gospodarowicz MK, Wittekind C. 2009, Wiley-Blackwell, Oxford UK, 243-248. 7
11.
Egevad L, Mazzucchelli R, Montironi R: Implications of the International Society of Urological Pathology modified Gleason grading system. Arch Pathol Lab Med. 2012, 136: 426-434. 10.5858/arpa.2011-0495-RA.PubMedCrossRef
12.
Epstein JI, Allsbrook WC, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005, 29: 1228-1242. 10.1097/01.pas.0000173646.99337.b1.PubMedCrossRef
13.
Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep. 1966, 50: 125-128.PubMed
14.
Caras RJ, Sterbis JR: Prostate cancer nomograms: a review of their use in cancer detection and treatment. Curr Urol Rep. 2014, 15: 391-10.1007/s11934-013-0391-0.PubMedCrossRef
15.
Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF, Vickers AJ: Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010, 58: 687-700. 10.1016/j.eururo.2010.07.034.PubMedPubMedCentralCrossRef
16.
Brawer MK, Bostwick DG, Benson MC, Djavan B, Lilja H, Semionow A, Su S, Zhou Z, Foster CS, Algaba F, Hutter RVP, Montironi R, Mostofi FK, Sark W, Sesterehenn I, Pow Sang J: Prostate tissues factor. Prostate Cancer. 2nd International Consultation on Prostate Cancer- 1999 Paris. Edited by: Murphy G, Khoury S, Partin A, Denis L. 2000, Plymbridge Distributors Ltd, Plymouth, UK, 162-201.
17.
Venkataraman G, Rycyna K, Rabanser A, Heinze G, Baesens BM, Ananthanarayanan V, Paner GP, Barkan GA, Flanigan RC, Wojcik EM: Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy. J Urol. 2009, 181: 88-93. 10.1016/j.juro.2008.09.013.PubMedCrossRef
18.
Baydar DE, Baseskioglu B, Ozen H, Geyik PO: Prognostic significance of lymphovascular invasion in clinically localized prostate cancer after radical prostatectomy. Sci World J. 2008, 8: 303-312. 10.1100/tsw.2008.49.CrossRef
19.
Brooks JP, Albert PS, O'Connell J, McLeod DG, Poggi MM: Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy. Cancer. 2006, 106: 1521-1526. 10.1002/cncr.21774.PubMedCrossRef
20.
Yee DS, Shariat SF, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA: Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 2011, 108: 502-507. 10.1111/j.1464-410X.2010.09848.x.PubMedPubMedCentralCrossRef
21.
Kothari PS, Scardino PT, Ohori M, Kattan MW, Wheeler TM: Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol. 2001, 25: 1429-1432. 10.1097/00000478-200111000-00012.PubMedCrossRef
22.
Hansen J, Budäus L, Spethmann J, Schlomm T, Salomon G, Rink M, Haese A, Steuber T, Heinzer H, Huland H, Graefen M, Michl U: Assessment of rates of lymph nodes and lymph node metastases in periprostatic fat pads in a consecutive cohort treated with retropubic radical prostatectomy. Urology. 2012, 80: 877-882. 10.1016/j.urology.2012.06.052.PubMedCrossRef
23.
von Bodman C, Godoy G, Chade DC, Cronin A, Tafe LJ, Fine SW, Laudone V, Scardino PT, Eastham JA: Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol. 2010, 184: 143-148. 10.1016/j.juro.2010.03.039.PubMedPubMedCentralCrossRef
24.
Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML: Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009, 55: 261-270. 10.1016/j.eururo.2008.09.043.PubMedCrossRef
25.
Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S: Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013, 123: 4918-4922. 10.1172/JCI70354.PubMedPubMedCentralCrossRef
Metadata
Title
Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?
Authors
Rodolfo Montironi
Marina Scarpelli
Roberta Mazzucchelli
Antonio Lopez-Beltran
Matteo Santoni
Alberto Briganti
Francesco Montorsi
Liang Cheng
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-014-0190-z

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue

Research

Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion

Research

RETRACTED ARTICLE: Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia

Research

Association between STAT3 gene Polymorphisms and Crohn’s diseasesusceptibility: a case–control study in a Chinese Han population

Research

Red blood cell distribution width is not correlated with preeclampsia among pregnant Sudanese women

Research

The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis

Research

MicroRNA-107 promotes proliferation of gastric cancer cells by targeting cyclin dependent kinase 8